# Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)

> **NCT00703365** · PHASE2 · COMPLETED · sponsor: **Mahidol University** · enrollment: 45 (actual)

## Conditions studied

- Carcinoma, Hepatocellular

## Interventions

- **DRUG:** Sorafenib and Gemcitabine

## Key facts

- **NCT ID:** NCT00703365
- **Lead sponsor:** Mahidol University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2010-01
- **Final completion:** 2011-08
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2011-08-29

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00703365

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00703365, "Efficacy and Safety of Sorafenib (Nexavar) in Combination With Gemcitabine in Advanced Hepatocellular Carcinoma (HCC)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00703365. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*